about
A new generation of human artificial chromosomes for functional genomics and gene therapyMolecular biology of lung cancerTyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsReview: the Contribution of both Nature and Nurture to Carcinogenesis and Progression in Solid TumoursMolecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinomacfDNA analysis from blood in melanomaUsing large-scale genomics data to identify driver mutations in lung cancer: methods and challengesFrom modules to medicine: How modular domains and their associated networks can enable personalized medicineConcurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: a review of the literatureTime to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinomaPreclinical Murine Models for Lung Cancer: Clinical Trial ApplicationsImmunotherapy in the treatment of non-small cell lung cancerPredictive models for customizing chemotherapy in advanced non-small cell lung cancer (NSCLC)The pivotal role of pathology in the management of lung cancerCancer concepts and principles: primer for the interventional oncologist-part IITumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesMutation of the BRAF genes in non-small cell lung cancerSuperbinder SH2 domains act as antagonists of cell signalingMolecular pathology of non-small cell lung cancer: a practical guide.Molecular pathology of lung cancer: key to personalized medicine.Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to dateSynthetic lethality in lung cancer and translation to clinical therapiesCirculating tumor cells versus circulating tumor DNA in lung cancer-which one will win?Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondNonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunopreventionOvine pulmonary adenocarcinoma: a large animal model for human lung cancerTRKing down an old oncogene in a new era of targeted therapyPI3K-independent AKT activation in cancers: a treasure trove for novel therapeuticsIdentification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokersLung cancer: prevalent trends & emerging conceptsCommon Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never SmokersPulmonary adenocarcinoma: a renewed entity in 2011Exhaled breath analysis for lung cancer detection using ion mobility spectrometry.Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancerBRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implicationsSilencing of Receptor Tyrosine Kinase ROR1 Inhibits Tumor-Cell Proliferation via PI3K/AKT/mTOR Signaling Pathway in Lung AdenocarcinomaThe eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing dataCharacteristics of lung cancers harboring NRAS mutationsAnti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cellsInhibition of breast cancer metastasis suppressor 1 promotes a mesenchymal phenotype in lung epithelial cells that express oncogenic K-RasV12 and loss of p53.
P2860
Q24599954-0F5D1B99-22BB-4D6B-8D9F-51B56D6811E6Q24606677-8388CB97-F8F5-482E-A6C9-AC51470EF055Q26741318-FE11CC26-CDD2-43B2-9E55-1FDCEAF721C7Q26749322-CCB6B4FC-ADFB-4B45-8C44-86EA0E5A1771Q26767182-D334C51F-978A-4A86-BD96-155C0C3F8DF4Q26772199-F7A2B8F4-C2BA-4BDC-9C9D-BED1C96D86AFQ26800833-F5D9EA51-66B2-41C5-B7DA-6026A8E5B7E2Q26830811-F3327AF9-DC4B-488B-9BEA-4F6713A32DA3Q26851579-01DAFD77-6710-4B27-86A4-35A80E799731Q26853261-142EBD01-BE4D-4FB1-8B35-374430D1FFBEQ26863474-FD6ABE8A-8788-46A6-9CB2-A58676BBA9A4Q27000382-CCE1D36E-08C3-40CF-B9F8-9AFA9567B923Q27009492-A7542C5C-05F1-41E8-A8CB-ED2A89EA5819Q27010437-A390D9AE-DBC0-4283-AE40-97EE729980F7Q27010961-87383450-79D0-439C-9606-48993E7B3DC1Q27014117-9B947928-8EE2-48CA-B4BF-A1B4BA5164D6Q27025345-4BEBD342-E04F-4228-85E4-CFD61B6EFEAAQ27682496-51064B44-76E9-467A-91FF-950607D93EAFQ27690919-40183A73-F359-429E-963B-0B574FB3ED2DQ27691299-CF46293F-A167-45F1-BEA5-CED488775961Q28067610-0726510F-FEAE-491A-A294-251DB85234C6Q28072904-9EC3B730-4A75-4C48-8574-0DEA010DC42FQ28077340-6869CF58-7940-422E-843D-9FB3D55F5612Q28080730-90AB34D1-B807-4AE3-BB22-CE283B40998FQ28082487-7BBD8BC1-7CB7-4CD9-B3B1-69C571E935FAQ28088774-38A77439-9DB7-4E57-8E21-3EBFEEED52E3Q28254287-5AD56734-51B9-41B1-8101-A724086940D9Q28259003-BA68CCAC-5947-4689-AEE3-F6DAC6292F14Q28383535-1AF7E215-C9DE-4DDF-AB8F-CAB355D01D4FQ28392286-A1BB09A4-C844-4547-871B-ED7C69628421Q28394324-AF84449B-373D-4616-A79E-697F87843435Q28395348-19869251-E92B-4F99-A9DA-A5832BDFC35FQ28542609-CCAFEBF4-C677-4A1A-A0DE-C290D60D56C8Q28542859-8BD0462F-1349-4E82-B925-D64127B2F456Q28543370-65BF7A24-D360-4F43-ACE1-6210FFFF65B2Q28547292-3312F346-2C04-4CF4-993B-330C731D797AQ28649714-27CA0E90-9604-4CE5-94BD-49060876E5A3Q28706226-AF05B18C-B272-454D-82E1-E4AF1DBD2C55Q28729071-16A999EB-C099-415A-83B2-01ED90F61D71Q30413635-E6889CD1-10C0-4DAC-BB76-A1C85D68A8A1
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
New driver mutations in non-small-cell lung cancer.
@ast
New driver mutations in non-small-cell lung cancer.
@en
New driver mutations in non-small-cell lung cancer.
@nl
type
label
New driver mutations in non-small-cell lung cancer.
@ast
New driver mutations in non-small-cell lung cancer.
@en
New driver mutations in non-small-cell lung cancer.
@nl
prefLabel
New driver mutations in non-small-cell lung cancer.
@ast
New driver mutations in non-small-cell lung cancer.
@en
New driver mutations in non-small-cell lung cancer.
@nl
P1433
P1476
New driver mutations in non-small-cell lung cancer.
@en
P2093
Nicolas Girard
P304
P356
10.1016/S1470-2045(10)70087-5
P50
P577
2011-02-01T00:00:00Z